구강내 악성흑색종에 대한 임상연구
The prognosis of oral malignant melanoma is poor compared with cutaneous melanoma. It may be related to the difficulty of wide enough resection, the early hematogenous matastases, higher stage at initial diagnosis, and tendency to growth vertically. In the view of histological differences between or...
Saved in:
Published in | Journal of the Korean Association of Oral and Maxillofacial Surgeons Vol. 34; no. 6; pp. 611 - 615 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | Korean |
Published |
대한구강악안면외과학회
30.12.2008
Korean Association Of Oral And Maxillofacial Surgeons |
Subjects | |
Online Access | Get full text |
ISSN | 2234-7550 2234-5930 |
Cover
Loading…
Summary: | The prognosis of oral malignant melanoma is poor compared with cutaneous melanoma. It may be related to the difficulty of wide enough resection,
the early hematogenous matastases, higher stage at initial diagnosis, and tendency to growth vertically. In the view of histological differences between
oral mucosa and skin, it is impossible use Clark’s and Breslow’s classifications for prognosis. The great problem is that there is still no consensus on
the treatment due to rarity .
Because data collection from case reports is considered to be the best source of information and should be pooled to analyze key determinants of
outcome, We analysed 6 cases of primary malignant melanoma of the oral cavity which were diagnosed and treated in Pusan National University
Hospital on recent 7 years and reviewed the literatures. Immunohistochemical study on S 100 Protein, GP 100 (HMB-45) with biopsy was usable to
confirm the melanoma. Three patients who were treated by surgery, chemotherapy are alive, but a patients who couldn’t received benefit care surgically
due to poor condition was died of distant metastasis, and two patients who refused to surgery are still alive.
Neck dissection including wide excision is recommended if lymph node involvement is suspected. Additionally, adjuvant chemotherapy could be
considered as supporting therapy for malignant melanoma. KCI Citation Count: 1 |
---|---|
Bibliography: | G704-000546.2008.34.6.003 |
ISSN: | 2234-7550 2234-5930 |